

Drugs Subject to Market Expansion Re-Pricing

Brand name		Generic name	Company	Specification	Current NHI price (yen)	Revised NHI price (yen)	Reduction rate (%)	Therapeutic category	Premium
1	Vyndaqel Capsules 20mg	tafamidis meglumine	Pfizer	20 mg/capsule	58,230.40	43,672.80	25.0	Agent for peripheral nerves	-
2	Samsca Tablets 7.5 mg	tolvaptan	Otsuka	7.5 mg/tablet	1,298.50	1,084.70	16.5	Diuretic Hormone preparation (including antihormone preparation)	-
	Samsca Tablets 15 mg			15 mg/tablet	1,975.40	1,650.10			
	Samsca Tablets 30 mg			30 mg/tablet	2,999.90	2,505.90			
	Samsca OD Tablets 7.5 mg			7.5 mg/tablet	1,298.50	1,084.70			
	Samsca OD Tablets 15 mg			15 mg/tablet	1,975.40	1,650.10			
	Samsca OD Tablets 30 mg			30 mg/tablet	2,999.90	2,505.90			
	Samsca Granules 1%			1%/1 g	1,931.00	1,613.00			
3	Feburic Tablets 10 mg	febuxostat	Teijin Pharma	10 mg/tablet	32.10	27.40	14.6	Gout treatment	-
	Feburic Tablets 20 mg			20 mg/tablet	58.60	50.10	14.5		
	Feburic Tablets 40 mg			40 mg/tablet	110.10	94.10	14.5		
	Uriadec Tablets 20 mg	topiroxostat	Sanwa Kagaku	20 mg/tablet	21.10	18.00	14.7	Gout treatment	-
	Uriadec Tablets 40 mg			40 mg/tablet	38.90	33.20	14.7		
	Uriadec Tablets 60 mg			60 mg/tablet	57.20	48.90	14.5		
	Topiloric Tablets 20 mg	topiroxostat	Fuji Yakuhin	20 mg/tablet	19.90	17.00	14.6	Gout treatment	-
	Topiloric Tablets 40 mg			40 mg/tablet	36.80	31.40	14.7		
	Topiloric Tablets 60 mg			60 mg/tablet	53.60	45.80	14.6		
4	Revlimid Capsules 2.5 mg Revlimid Capsules 5 mg	lenalidomide hydrate	Celgene	2.5 mg/capsule 5 mg/capsule	7,981.10 9,512.10	6,783.90 8,085.30	15.0	Antitumor agent	-
5	Lynparza Tablets 100 mg Lynparza Tablets 150 mg	olaparib	AZ	100 mg/tablet 150 mg/tablet	4,070.00 6,042.40	3,492.60 5,185.10	14.2	Antitumor agent	5%
6	Stelara SC Injection 45 mg Syringe	ustekinumab (recombinant)	Janssen	45 mg/0.5 mL/syringe	445,131	381,818	14.2	Metabolism agent	-
7	Perjeta for IV Infusion 420 mg/14 mL	pertuzumab (recombinant)	Chugai	420 mg/14 mL/vial	242,908	206,472	15.0	Antitumor agent	-
8	Faslodex IM Injection 250 mg	fulvestrant	AZ	250 mg/5 mL/syringe	51,733	38,801	25.0	Antitumor agent	5%
9	Dupixent SC Injection 300 mg Syringe	dupilumab (recombinant)	Sanofi	300 mg/2 mL/syringe	83,152	66,356	20.2	Anti-allergic agent	-
10	Hemlibra for SC Injection 30 mg Hemlibra for SC Injection 60 mg Hemlibra for SC Injection 90 mg Hemlibra for SC Injection 105 mg Hemlibra for SC Injection 150 mg	emicizumab (recombinant)	Chugai	30 mg/1 mL/vial	382,969	325,524	15.0	Blood preparation	-
				60 mg/0.4 mL/vial	705,390	599,582			
				90 mg/0.6 mL/vial	1,008,323	857,075			
				105 mg/0.7 mL/vial	1,155,029	981,775			
				150 mg/1 mL/vial	1,581,580	1,344,343			
11	Actemra IV Infusion 80 mg Actemra IV Infusion 200 mg Actemra IV infusion 400 mg Actemra 162 mg Syringe for SC Injection Actemra 162 mg Auto-Injector for SC Injection	tocilizumab (recombinant)	Chugai	80 mg/4 mL/vial	18,936	15,429	18.5	Biologic	-
				200 mg/10 mL/vial	46,653	38,014			
				400 mg/20 mL/vial	92,289	75,198			
				162 mg/0.9 mL/syringe	39,868	32,485			
				162 mg/0.9 mL/kit	40,019	32,608			
	Kevzara 150 mg Syringe SC Injection Kevzara 200 mg Syringe SC Injection Kevzara 150 mg SC Autoinjector Kevzara 200 mg SC Autoinjector	sarilumab (recombinant)	Sanofi	150 mg/1.14 mL/syringe	45,202	36,831	18.5	Metabolism agent	-
				200 mg/1.14 mL/syringe	59,802	48,728			
				150 mg/1.14 mL/kit	45,596	37,152			
				200 mg/1.14 mL/kit	60,195	49,048			
12	Diquas Ophthalmic Solution 3%	diquafosol sodium	Santen	3%/5 mL/vial	648.70	532.80	17.9	Ophthalmic agent	-

Note:

- In the FY2020 revision, NHI prices will be set at the lower of the following two prices:

- 1) Prices calculated by the market expansion re-pricing scheme
- 2) Prices calculated based on the formula using the actual market prices

- Tolvaptan and tocilizumab (recombinant) are subject to a special calculation rule for drugs that have gone through market expansion re-pricing in the past.

- The following APIs have pharmacological profiles similar to the above to-be-re-priced drugs, but were exempted from re-pricing because they were deemed to lack competitiveness in their markets: 1) thalidomide, pomalidomide (drugs similar to Revlimid), 2) Stelara IV Infusion 130 mg (ustekinumab (recombinant)), 3) trastuzumab (drug similar to Perjeta)

Drugs Subject to Special Expansion Re-Pricing (Huge-Seller Re-Pricing)

Brand name		Generic name	Company	Specification	Current NHI price (yen)	Revised NHI price (yen)	Reduction rate (%)	Therapeutic category	Premium
1	Lixiana Tablets 15 mg	edoxaban tosilate hydrate	Daiichi Sankyo	15 mg/tablet	299.60	224.70	25.0	Anticoagulant	-
	Lixiana Tablets 30 mg			30 mg/tablet	548.40	411.30			
	Lixiana Tablets 60 mg			60 mg/tablet	555.70	416.80			
	Lixiana OD Tablets 15 mg			15 mg/tablet	299.60	224.70			
	Lixiana OD Tablets 30 mg			30 mg/tablet	548.40	411.30			
	Lixiana OD Tablets 60 mg			60 mg/tablet	555.70	416.80			
2	Keytruda Injection 100 mg	pembrolizumab (recombinant)	MSD	100 mg/4 mL/vial	306,231	242,355	20.9	Antitumor agent	-

Note:

- In the FY2020 revision, NHI prices will be set at the lower of the following two prices:

- 1) Prices calculated by the market expansion re-pricing scheme (including special market expansion re-pricing)
- 2) Prices calculated based on the formula using the actual market prices

Drugs Subject to Indication Change Re-Pricing

Brand name		Generic name	Company	Specification	Current NHI price (yen)	Revised NHI price (yen)	Reduction rate (%)	Therapeutic category	Premium
1	Xolair for SC Injection 75 mg	omalizumab (recombinant)	Novartis	75 mg/vial	23,556	14,768	37.3	Respiratory organ agent Anti-allergic agent	-
	Xolair for SC Injection 150 mg			150 mg/vial	46,422	29,104			
	Xolair for SC Injection 75 mg Syringe			75 mg/0.5 mL/vial	23,625	14,812			
	Xolair for SC Injection 150 mg Syringe			150 mg/1 mL/vial	46,490	29,147			

Note:

* Xolair's main indication, which had been bronchial asthma (only intractable cases with symptoms that cannot be adequately controlled with existing treatments), was changed in line with the addition of a new indication for seasonal allergic rhinitis (in severe or most severe patients who are refractory to existing treatments) in December 2019.

(Source: Chuikyo/Edited by PHARMA JAPAN)